Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review status for its dexmethylphenidate hydrochloride sustained release capsules, which are being developed for potential pediatric use. The molecule is intended to treat attention deficit hyperactivity disorder (ADHD) in children.
Phase III Clinical Study and Efficacy
The product, classified as a central nervous system stimulant and supported by the national major special variety program, completed its Phase III clinical study in children with ADHD in October 2019. The study demonstrated significant efficacy in treating the condition, with no severe adverse events reported. This successful trial outcome positions the drug as a strong candidate for priority review, reflecting its potential to make a significant impact on pediatric ADHD treatment.
Potential Impact on Pediatric ADHD Treatment
The dexmethylphenidate hydrochloride sustained release capsules by Henan Zhongshuai Pharmaceutical represent an important advancement in the management of ADHD in children. With the potential for priority review status, the drug could become an essential tool in the treatment arsenal for healthcare providers, offering a new option for children struggling with ADHD.-Fineline Info & Tech
